The c-Cbl Antibody Sampler Kit provides an economical means of evaluating levels of c-Cbl protein phosphorylated at the specified sites, as well as total c-Cbl levels. The kit contains enough reagents to perform four western blot experiments per primary antibody.
The Phospho-c-Cbl (Tyr700) and (Tyr731) Antibodies detect endogenous c-Cbl when phosphorylated at the specified sites. c-Cbl (C49H3) Rabbit mAb detects endogenous levels of total c-Cbl protein.
The phospho-specific polyclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr731 of human c-Cbl. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. The monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to the sequence of human c-Cbl and residues surrounding Tyr700 of human c-Cbl.
The c-Cbl proto-oncogene is a ubiquitously expressed cytoplasmic adaptor protein that is especially predominant in hematopoietic cells (1,2). c-Cbl is rapidly tyrosine-phosphorylated in response to stimulation of a variety of cell-surface receptors and becomes associated with a number of intracellular signaling molecules such as protein tyrosine kinases, phosphatidylinositol-3 kinase, Crk, and 14-3-3 proteins (3,4). c-Cbl possesses a highly conserved amino-terminal phosphotyrosine binding domain (TKB) and a C3HC4 RING finger motif. The TKB recognizes phosphorylated tyrosines on activated receptor tyrosine kinases (RTKs) as well as other nonreceptor tyrosine kinases. The RING finger motif recruits ubiquitin-conjugating enzymes. These two domains are primarily responsible for the ubiquitin ligase activity of c-Cbl and downregulation of RTKs (3). Research studies have indicated that in human cancer tissues, c-Cbl is frequently tyrosine-phosphorylated in a tumor-specific manner (5). Phosphorylation of Tyr731 of c-Cbl provides a docking site for downstream signaling components such as p85 and Fyn (6).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
Explore pathways related to this product.